Technologies

The compact-GC platform is a MEMS-based analytical module for the purge&trap pre-concentration and (gas)-chromatographic separation of a sample. The two analytical MEMS (pre-concentrator and GC column) are interconnected by means of a MEMS microfluidic manifold. The microfluidic manifold interconnects the analytical MEMS, but it also acts as injector through the integrated micro-valves.

We propose a portable chemical analysis system capable of identifying chemical substances at trace concentrations (sub-ppm), even in case of a complex matrix of interfering species.

This technology concerns the development of new eco-sustainable UV physical/mineral filters with the aim of offering important innovations per the cosmetic sector. This, encouraged by European initiatives in the Green-Deal context, is constantly looking for new components with improved protection of the human health and the environment.

Extracellular vesicles produced by teratocarcinoma cells were isolated and characterized. Functional assays on glioblastoma (GBM) cell cultures showed the inhibitory effect of these vesicles on tumor cell migration, without inducing undesirable effects such as increased cell proliferation or chemotherapy resistance.

This invention comprises an interrogation and readout differential method for chemical sensors based on Surface Plasmon Resonances (SPR). The integration of the SPR sensing unit (chip or other), as intermediate reflecting element of a Fabry-Perot (FP) optical resonator, is the starting point for the application of this method.

Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.

With the advent of senolytic agents, capable of selectively removing senescent cells in “aged” tissues, the perception of age-associated diseases has changed from being an inevitable to a preventable phenomenon of human life. The present invention is part of this research topic with the identification of molecules with potential pro-apoptotic activity, specifically with senolytic activity. The computational approach adopted, is based on combining ligand-base and structure-based virtual screening.

Filamentous bacteriophages for size, in vivo biodistribution and easiness of engineering, are considered as natural nanoparticles. The developed technology allows the construction of bio-nanoparticles based on filamentous bacteriophages delivering proteic antigens and immunomodulating lipids. Thanks to the high content of hydrophobic residues, phage capsid proteins have high binding affinity to lipids, allowing the conjugation of immunostimulating lipids.

This form describes a programmable, autonomous and stand-alone imaging system for the acquisition and processing of images containing subjects whose size is larger than 1cm (e.g. gelatinous zooplankton, fishes, litter, manufacts), form the seafloor or along the water column, in shallow or deep waters. It is capable to recognize and classify the image content through pattern recognition algorithms that combine computer vision and artificial intelligence methodologies.

We present a technology for the multiscale isolation (analytical-laboratory-production) of Extracellular Vesicles (VE), which overcomes the limitations of the currently available methods. As opposed to traditional "affinity-based" systems that exploit antibodies, our technology represents a radical paradigm shift in the development of affinity probes for vesicles, i.e.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.